VB119 for Focal Segmental Glomerulosclerosis
Trial Summary
What is the purpose of this trial?
This trial is testing a new treatment called VB119 to see if it can help keep certain kidney diseases under control. It focuses on adults with specific kidney conditions (MCD or FSGS) who have shown improvement with previous treatments. The goal is to see if VB119 can maintain their improvement and make it last longer.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you must be on a stable dose of prednisone (a type of steroid) of no more than 20 mg/day for at least 14 days before starting the trial.
Research Team
Keenan
Principal Investigator
ValenzaBio, Inc.
Eligibility Criteria
Adults over 18 with a kidney biopsy-proven diagnosis of primary MCD or FSGS within the last 10-20 years, who responded to steroids before and have had significant proteinuria in the past 2 years. Participants must be on a stable prednisone dose and have controlled blood pressure. Women must be non-childbearing or use contraception; men agree not to donate sperm for 4 months post-trial.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive VB119 100 or 200mg IV doses administered 4 times
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- VB119
Find a Clinic Near You
Who Is Running the Clinical Trial?
Tenet Medicines
Lead Sponsor
ValenzaBio, Inc.
Lead Sponsor
ACELYRIN Inc.
Lead Sponsor